focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: 0.075 (1.03%)
Spread: 0.25 (3.448%)
Open: 7.30
High: 7.375
Low: 7.30
Prev. Close: 7.30
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Oct 2009 09:42

RNS Number : 2842B
Phytopharm PLC
23 October 2009
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Phytopharm plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

Barclays plc

4. Full name of shareholder(s)  (if different from 3.):iv

Barclays Bank Trust Company Limited Barclays Stockbrokers Limited

Gerrard Investment Management Limited

5. Date of the transaction and date on which the threshold is crossed or reached: v

15 October 2009

6. Date on which issuer notified:

22 October 2009

7. Threshold(s) that is/are crossed or reached: vi, vii

5%

  

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0006869720

2,844

2,844

4,950,353

0

4,950,353

0

5.24

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

4,950,353

5.24

  

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Barclays Bank Trust Company Limited Barclays Stockbrokers Limited

Gerrard Investment Management Limited

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Zoe McGowan

15. Contact telephone number:

01480 437697

  

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name 

(including legal form of legal entities)

Contact address 

(registered office for legal entities)

Phone number & email

Other useful information 

(at least legal representative for legal persons)

B: Identity of the notifier, if applicable

Full name

Contact address

Phone number & email

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLVXLBLKBBXFBK
Date   Source Headline
21st Jan 202111:05 amRNSResult of AGM
7th Jan 20217:00 amRNSIssue of Equity
24th Dec 20207:00 amRNSIXICO secures new contract for £3.4 million
14th Dec 202011:54 amRNSHolding(s) in Company
8th Dec 20207:00 amRNSIXICO contract with new large global pharma
3rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
3rd Dec 20202:01 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFinancial Results for the year ended 30 Sept 2020
27th Nov 20207:00 amRNSIXICO announces £1.9 million new study award
9th Nov 20207:00 amRNSNotice of Results
3rd Nov 20207:00 amRNSAdditional Alzheimer’s disease contracts
22nd Oct 20207:00 amRNSFurther Huntington’s disease contracts
19th Oct 20207:00 amRNSIXICO to Present at SCA & ARCA Global Conference
19th Oct 20207:00 amRNSTrading Update for year ended 30 September 2020
16th Oct 20207:00 amRNSIXICO and NYU Langone Health sign agreement
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNS>£2m contract extension win - Huntington’s disease
24th Sep 20207:00 amRNSCollaboration with TRACK-FA NeuroimagingConsortium
21st Sep 20207:00 amRNSIXICO selected to support Alzheimer’s trial
11th Sep 202010:36 amRNSHolding(s) in Company
26th Aug 202011:55 amRNSInvestor presentation
24th Aug 20209:05 amRNSSecond Price Monitoring Extn
24th Aug 20209:00 amRNSPrice Monitoring Extension
24th Aug 20207:00 amRNSTrading Update
13th Aug 20207:00 amRNSInvestor Presentation
8th Jul 20207:00 amRNSConference attendance - On Helix Digital
6th Jul 20207:00 amRNSGrant of share options
24th Jun 20207:00 amRNSTrading Update
20th May 20207:00 amRNSHalf yearly report to 31 March 2020
12th May 20207:00 amRNSNotice of Results
20th Apr 20207:00 amRNSTrading update for H1 2020
14th Apr 20207:00 amRNS£10.5m contract win, update on trading & COVID-19
16th Mar 20209:00 amRNSIXICO announces expanded contract with Vaccinex
2nd Mar 202011:05 amRNSSecond Price Monitoring Extn
2nd Mar 202011:00 amRNSPrice Monitoring Extension
26th Feb 202011:05 amRNSSecond Price Monitoring Extn
26th Feb 202011:00 amRNSPrice Monitoring Extension
19th Feb 20209:00 amRNSIXICO to Present AI Segmentation Research
17th Feb 20204:40 pmRNSSecond Price Monitoring Extn
17th Feb 20204:35 pmRNSPrice Monitoring Extension
17th Feb 20202:05 pmRNSSecond Price Monitoring Extn
17th Feb 20202:00 pmRNSPrice Monitoring Extension
11th Feb 20207:00 amRNSHolding(s) in Company
10th Feb 20209:11 amRNSIXICO to Present at Innovation Forum
3rd Feb 20209:00 amRNSIXICO Supports the AD Neuroimaging Initiative
23rd Jan 20207:00 amRNSDirector/PDMR Shareholding
17th Jan 20204:34 pmRNSResult of AGM
15th Jan 202010:32 amRNSDirector/PDMR Shareholding
13th Jan 20201:29 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.